1Shapiro O, Jones K, Wang C, et al. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection[J]. The Canadian journal of urology, 2006, 13:3317 - 3320.
2Mutlu N, Turkeri L, Emerk K. Analytical and clinical evaluation of a new urinary tumor marker:bladder tumor fibronectin in diagnosis and follow - up of bladder cancer[J]. Clinical chemistry and laboratory medicine, 2003,41 : 1069 - 1074.
3Morales A, Eidinger D, Bruce AW. Intracavity bacillus calmetteguerin in the treatment of saperficial bladder tumor[J]. The Journal of Urology, 1976,116 : 180 - 183.
4Mukherjee A, Persad R, Smith PJ. Intravesical BCG treatment for superficial bladder cancer: long-term results using two different strains of BCG[J]. British journal of urology, 1992,69 : 147 - 150.
5Chin JL, Kadhim SA, Batislam E, et al. Mycobacterium cell wall., an alternative to intravesical bacillus Calmette Guerln (BCG) therapy in orthotopic murine bladder cancer [ J ]. The Journal of urology, 1996,156:1189 - 1193.
6Seya T,Akazawa T,Uehori J, et al. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer [ J ]. Anticancer research, 2003,23:4369 - 4376.
7Cheadle EJ, Selby PJ, Jackson AM. Mycobacterium bovis bacillus Calmette-Guerin-infected dendritic cells potently activate autologous T cells via a B7 and interleukin- 12 - dependent mechanism[J]. Immunology, 2003,108 : 79 - 88.
8Brandau S, Riemensberger J ,Jacobsen M, et al. NK cells are essential for effective BCG immunotherapy[J]. International Journal of Cancer, 2001,92 : 697 - 702.
9Mizutani Y, Yoshida O. In vitro enhancement of natural killer cell activity by BCG and the antagonistic inhibition of the susceptibility of K562 cells to lysis by peripheral blood lyrnphocytes in patients with urinary bladder tumor[M]. International journal of urology: official journal of the Japanese Urological Association, 1994:49 - 56.
10Fontana D, Bellina M, Galietti F, et al, Intravesical bacillus calmette-guerin (BCG) as inducer of tumor-suppressing proteins p53 and p21 Waft - Cipi during treatment of superficial bladder cancer [J]. The Journal of Urology, 1999,162:225 - 230.
二级参考文献9
1Lamm DL,Stogdill VD, Stogdill BJ, et aL Complication of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol, 1986, 135:272-274.
2Shen Z J, Jin XD, Lu YL. Experimental study of fibronectin mediated drug resistance in chemotherapy for bladder cancer. Int J Urol, 2002,9 Suppl:A33.
3Steg A, Leleu C, Debre B, et al. Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer. Prog Clin Biol Res, 1989, 310:325-334.
4Rafliff TL, Palmer JO, McGarr JA, et al. Intraversical bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by llbronectin-mediated attachment of bacillus Cametle-Guerin. Cancer Res, 1987, 47:1762-1766.
5Rafliff TL, Kavoussi LR, Catalona WJ. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer.J Urol,1988, 139:410-414.
6Hudson MA, Yuan JJ, Catalona WJ, et al.Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors. J Urol, 1990, 144 : 1362-1364.
7Hudson MA, Brown EJ, Ritchey JK, et al. Modulation of fibronectin-mediated bacillus Calmette-Guerin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res. 1991. 51:3726-3732.
